1. Introduction {#sec1-antibiotics-09-00388}
===============

Ceftazidime-avibactam (CZA) is a combination of the third-generation cephalosporin ceftazidime and a novel non-beta-lactam beta-lactamase inhibitor avibactam. It is a first line therapy for difficult-to-treat infections due to Gram-negative bacilli (GNB) \[[@B1-antibiotics-09-00388]\]. The prevalence of resistant GNB, including carbapenem-resistant Enterobacteriaceae (CRE) and Pseudomonas aeruginosa, is increasing worldwide. Infections due to CRE are associated with a mortality rate up to 50% \[[@B2-antibiotics-09-00388]\]. CZA treatment indications are similar in the United States (US) and Europe; the U.S. Food and Drug Administration (FDA) approved CZA in 2015 for the treatment of complicated intra-abdominal infections (cIAI), in combination with metronidazole, and for complicated urinary tract infections (cUTI), including pyelonephritis, in adult patients with limited or no alternative treatment options \[[@B3-antibiotics-09-00388]\]. The European Medicines Agency (EMA) approved CZA in 2016 for the treatment of adults with cUTIs, cIAIs (in association with metronidazole or an antibacterial agent active against Gram-positive pathogens), and hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP) \[[@B4-antibiotics-09-00388]\]. Several studies reported the use of CZA in difficult-to-treat CRE infections, mostly bloodstream infections (BSIs), alone or in combination of other antibiotics \[[@B5-antibiotics-09-00388],[@B6-antibiotics-09-00388],[@B7-antibiotics-09-00388],[@B8-antibiotics-09-00388]\]. The CZA off-label use in BSIs may be due to the lack of effective therapeutic options. Network meta-analysis (NMA), also known as multiple treatment meta-analysis, has been increasingly used in recent years with the aim to simultaneously compare the effects of multiple treatments on a health-related outcome \[[@B9-antibiotics-09-00388],[@B10-antibiotics-09-00388]\]. We performed a systematic review and NMA to compare the effectiveness of CZA mono versus combination therapy with other antibiotics in terms of mortality in patients with CRE infections.

2. Methods {#sec2-antibiotics-09-00388}
==========

The protocol was prospectively registered in PROSPERO (CRD42019128927) on April 16, 2019 \[[@B11-antibiotics-09-00388]\], after a search of the main electronic registries (Cochrane Database of Systematic Reviews, the JBI Database of Systematic Reviews and Implementation Reports and PROSPERO), to exclude overlap. The present systematic review was conducted according to PRISMA methodology \[[@B12-antibiotics-09-00388]\].

2.1. Study Search {#sec2dot1-antibiotics-09-00388}
-----------------

[Table 1](#antibiotics-09-00388-t001){ref-type="table"} shows the review question according to the PICOS format. The databases of the search included MEDLINE via PubMed, EMBASE, and Cochrane Central Register of Controlled Trials (CENTRAL). The full search strategies are reported in the [Table S1](#app1-antibiotics-09-00388){ref-type="app"}. The first search was performed until 4 April 2019; the search was re-run, updating the data collection definitively until 12 February 2020.

2.2. Study Selection {#sec2dot2-antibiotics-09-00388}
--------------------

We included both randomized controlled trials (RCTs) and nonrandomized studies (both prospective and retrospective), published in English language and in peer-reviewed journals. No restriction on time of publication was applied.

[Figure 1](#antibiotics-09-00388-f001){ref-type="fig"} shows the inclusion--exclusion process according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) flow diagram. After the searches, duplicates were removed using a citation management software (Endnote VX9. Clarivate Analytics, PA, USA) and a list of all included studies was created. Two authors (SDF and GI) independently performed a screening of retrieved articles based on titles and abstract. The same authors independently evaluated the full texts of the selected articles for final inclusion. The standardized reasons for exclusion were recorded.

Any disagreements on study eligibility or data extraction were resolved according to a third reviewer's opinion (AC).

2.3. Definition and Outcome {#sec2dot3-antibiotics-09-00388}
---------------------------

The primary outcome was all-cause mortality evaluated at the longest reported follow-up (if multiple time-points were considered by the authors of the included studies) in the microbiologically evaluable population. The microbiologically evaluable population included all patients who had a diagnosis of infection with at least one pathogen, as confirmed by the laboratory. We did not consider patients with no culture or negative culture. The secondary outcomes were the non-microbiological improvement and the non-clinical improvement.

2.4. Data Extraction and Quality Assessment {#sec2dot4-antibiotics-09-00388}
-------------------------------------------

Data were extracted from studies included in the review by two reviewers independently (AC, MF) using the Cochrane data collection form for intervention reviews for RCTs and non-RCTs \[[@B13-antibiotics-09-00388]\]. Two authors assessed the methodological quality of the included studies (AC, MF). The risk of bias of enrolled RCTs was evaluated using the Cochrane Collaboration Revised Assessment Tool (RoB 2) \[[@B14-antibiotics-09-00388]\]. The quality of nonrandomized studies was assessed using the Newcastle-Ottawa Assessment Scale (NOS) \[[@B15-antibiotics-09-00388]\].

2.5. Data Analysis {#sec2dot5-antibiotics-09-00388}
------------------

We used NMA for synthesizing information and pooled estimates based on the frequentist approach, using the statistical package 'netmeta' (version 1.2-0) in R \[[@B16-antibiotics-09-00388]\]. For a given comparison (A vs B), direct evidence is usually provided by studies that compare these treatments directly. The NMA function provides a back-calculation method to derive indirect estimates from direct pairwise comparisons and combines both direct and indirect evidence across a network of studies into a single effect size. Q and I^2^ statistics were used to quantify heterogeneity among included studies, with I^2^ \< 50% indicating no heterogeneity and I^2^ ≥ 50% indicating significant heterogeneity. A random-effects model was conducted in case of significant heterogeneity; otherwise, a fixed-effect model was applied. Q statistic was evaluated for both heterogeneity (within designs) and inconsistency (between designs). Plot of direct evidence proportion for each network estimate was proposed with minimal parallelism and mean path length metrics \[[@B17-antibiotics-09-00388]\]. Furthermore, a net heat plot was used to evaluate cases of inconsistency between direct and indirect evidence \[[@B18-antibiotics-09-00388]\].

The main outcome of this NMA and of each single study was mortality. This outcome was pooled as odds ratio (OR) with 95% confidence interval (CI). The ranking probability P-score was used to rank different treatments, where a larger value indicates better performance. This pooled outcome was furthermore analyzed using node splitting method which allows us to control for inconsistency in specific comparisons in our network and graphically represented with a forest plot. All analyses were performed using R software version 3.6.2.

3. Results {#sec3-antibiotics-09-00388}
==========

3.1. Study Selection and Characteristics {#sec3dot1-antibiotics-09-00388}
----------------------------------------

We retrieved 2039 articles from the database searches: 1202 on PubMed, 758 on EMBASE, and 79 on CENTRAL. After the removal of 922 duplicates, 1117 articles were identified as potentially relevant and screened as shown in the flow chart ([Figure 1](#antibiotics-09-00388-f001){ref-type="fig"}). After the screening of titles and abstracts, the full text of 60 articles were evaluated. We further excluded 47 studies for 8 main reasons ([Figure 1](#antibiotics-09-00388-f001){ref-type="fig"}). Thirteen studies were finally included in the qualitative synthesis ([Table 2](#antibiotics-09-00388-t002){ref-type="table"}) and 6 studies in the final meta-analysis ([Table 3](#antibiotics-09-00388-t003){ref-type="table"}).

Of the 13 studies included in the qualitative synthesis, of these, 7 were RCT and 6 retrospective cohort studies. The overall risk of bias of the 7 RCT, was low ([Supplementary Table S2](#app1-antibiotics-09-00388){ref-type="app"}); the quality of the 6 retrospective studies, assessed using the New Castle-Ottawa Scale \[[@B15-antibiotics-09-00388]\], was moderate-high ([Supplementary Table S3](#app1-antibiotics-09-00388){ref-type="app"}). Only 2 of the 7 RCT evaluated mortality as outcome \[[@B19-antibiotics-09-00388],[@B20-antibiotics-09-00388]\], with a total of 261 patients treated with CZA and 266 not treated with CZA. The microbiological outcome (microbiological non improvement/cure) and the clinical outcome (non clinical improvement/cure) were evaluated in all the 7 RCT. The microbiological outcome, in patients undergoing a pathogen-directed therapy, was evaluated in 2366 patients (1162 patients treated with a CZA-based therapy and 1204 patients treated with other antibiotic treatment). The clinical outcome was evaluated in a total of 2615 patients (1277 patients treated with a CZA-based therapy and 1338 patients treated with other antibiotic treatment).

Three of the 7 RCT enrolled patients with complicated intra-abdominal infections (cIAI) \[[@B21-antibiotics-09-00388],[@B22-antibiotics-09-00388],[@B23-antibiotics-09-00388]\], two enrolled patients with complicated urinary tract infection (cUTI) \[[@B24-antibiotics-09-00388],[@B25-antibiotics-09-00388]\], and one enrolled patient with nosocomial pneumonia (NP) \[[@B18-antibiotics-09-00388]\]. One RCT enrolled patient with both cUTI or cIAI \[[@B19-antibiotics-09-00388]\]. The 7 RCT enrolled patients infected by bacteria not exclusively belonging to CRE.

Conversely, in all the retrospective studies, the enrolled patients were infected by CRE only; in 4 retrospective studies, the authors enrolled patients with infections caused by all CRE \[[@B6-antibiotics-09-00388],[@B8-antibiotics-09-00388],[@B26-antibiotics-09-00388],[@B27-antibiotics-09-00388]\] and in 2 studies, only Klebsiella pneumoniae carbapenemase (KPC)-producing \[[@B5-antibiotics-09-00388],[@B7-antibiotics-09-00388]\], Klebsiella pneumoniae belongs to the tribe Klebsiellae, a member of the Enterobacteriaceae family \[[@B28-antibiotics-09-00388]\]. In the studies included in the NMA, the authors have adopted a phenotypic definition of resistance to carbapenems (i.e., based on the antibiotic susceptibility pattern). The focus of infection in the 83% (419/503) of patients was bacteremia; only in 3 of these 6 retrospective studies bacteremia was aggregated with other focus of infection: In the study by King et al. \[[@B26-antibiotics-09-00388]\], two fifths of the patients (23/60) had bacteremia, in the study by Sousa et al. \[[@B8-antibiotics-09-00388]\], almost half of the patients (26/57) have bacteremia. In the study by Alraddadi et al. \[[@B27-antibiotics-09-00388]\], more than a half of patients (22/38) have bacteremia.

For the quantitative evaluation, we decided to meta-analyze the studies in which the infection was caused by pathogens resistant to carbapenems.

3.2. NMA Heterogeneity and Inconsistency Evaluation {#sec3dot2-antibiotics-09-00388}
---------------------------------------------------

There is no statistical heterogeneity among included studies, with I^2^ 0% (95% CI; 0--17.9%) and thereby a fixed-effect model was applied. The Q statistic was 0.62 (*p* = 0.89) for the within design and 1.48 (*p* = 0.69) for the between design indicating again no heterogeneity and consistency of model used.

As showed in [Figure 2](#antibiotics-09-00388-f002){ref-type="fig"}, more than 75% of each comparison is represented by direct proportion. Minimal parallelism is always higher than 1 and mean path length lower than 2, showing good metrics as reported by Konig and colleagues \[[@B17-antibiotics-09-00388]\]. The net heat plot confirms the consistency of data and studies in this NMA \[[@B29-antibiotics-09-00388]\] ([Figure 3](#antibiotics-09-00388-f003){ref-type="fig"}).

3.3. Mortality {#sec3dot3-antibiotics-09-00388}
--------------

We planned to analyze the longest follow-up, if the mortality was reported at different time-points; in 5 of 6 retrospective studies, included in the NMA, the longest follow-up was 30-day-mortality ([Table 2](#antibiotics-09-00388-t002){ref-type="table"}).

The NMA, including 503 patients, did not show significant differences in CZA-combination therapy compared to CZA-monotherapy \[OR: 0.96, 95% CI: 0.65--1.41\]. A significant difference was observed in both CZA-monotherapy vs. best available antibiotic therapy (BAT) \[OR: 0.68, 95% CI: 0.48--0.98\] and CZA-combination vs. BAT \[OR: 0.66, 95% CI: 0.48--0.89\], the forest plot is shown in [Figure 4](#antibiotics-09-00388-f004){ref-type="fig"}. As a whole, the ranking probability P-score showed a larger value for CZA-combination therapy (0.7917) and CZA-monotherapy (0.6965) with the lowest rank score for the BAT (0.0118).

Non-clinical improvement was evaluated in only 4 studies \[[@B6-antibiotics-09-00388],[@B8-antibiotics-09-00388],[@B26-antibiotics-09-00388],[@B27-antibiotics-09-00388]\], including 186 patients and microbiological failure was evaluated in only 4 studies \[[@B5-antibiotics-09-00388],[@B8-antibiotics-09-00388],[@B26-antibiotics-09-00388],[@B27-antibiotics-09-00388]\], including 363 patients ([Table 2](#antibiotics-09-00388-t002){ref-type="table"}). Therefore, due to the small number of patients, we did not proceed to quantitative synthesis for the secondary outcomes.

4. Discussion {#sec4-antibiotics-09-00388}
=============

The main findings of this study were that there were no significant differences in mortality in the treatment of CRE infections with CZA-combination therapy compared to CZA-monotherapy, based on available evidence.

Transmissible carbapenem-resistance in Enterobacteriaceae, among which the KPCs are the most notorious, has been reported since twenty years, but only recently it has been expressed as a public health problem with outbreaks reported worldwide \[[@B31-antibiotics-09-00388],[@B32-antibiotics-09-00388],[@B33-antibiotics-09-00388],[@B34-antibiotics-09-00388]\]; CRE, due to the difficulty of effective treatment and the very high attributable mortality, are also known as "nightmare bacteria" \[[@B2-antibiotics-09-00388]\]. Infections caused by these bacteria are associated with a mortality rate exceeding 50%. Since the burden of this problem is dramatic, the introduction of new antibiotics or the alternative use of existing antibiotics, as well as in our study exploring the off-label use of CZA in BSIs, is indispensable.

The Infectious Disease Society of America recommends the development of new antibiotic options through pathogen-directed studies, in which patients with multiple disease types are enrolled, rather than a single type of infection \[[@B35-antibiotics-09-00388]\].

For these premises, we have meta-analyzed cumulates results from pathogen-directed studies, enrolling patients with different types of infection; for more than four-fifths of the patients, the infection focus was a BSI. Therefore, although the number of included patients is relatively low, the review cohort is homogeneous. We decided to explore as primary outcome the all-cause mortality because it is highly objective, accurate, and simple to measure \[[@B36-antibiotics-09-00388]\], especially in case of low-quality evidence.

No difference in mortality rate was observed in patients undergoing CZA combination therapy compared to those who received CZA monotherapy for the treatment of CRE infections. This finding may be useful for optimizing the antibiotic treatment, with the potential to reduce the use of combination treatments \[[@B37-antibiotics-09-00388]\].

Our results should be considered in light of some limitations. The outcome of mortality was not assessed in all studies at the same time point, although in the vast majority of studies (83%: 5/6), it was assessed at 30 days ([Table 3](#antibiotics-09-00388-t003){ref-type="table"}). We used raw data from observational studies, and this approach is prone to the effect of potential confounders \[[@B38-antibiotics-09-00388]\]. Our results cannot be extrapolated to infections other than due to CRE and should be carefully considered when treating patients with high severity of diseases. Moreover, local epidemiology should be considered when deciding to use CZA mono- or combination therapy. Due to the small number of studies and patients, we were not able to explore the secondary outcomes. Furthermore, we did not consider the side effect of antibiotics among the outcomes \[[@B11-antibiotics-09-00388]\]. A limitation of our study is that a phenotypic diagnosis of resistance to carbapenems was adopted; there are many different mechanisms (i.e., genotypes) that can result in carbapenem resistance, while phenotypic tests are easy and cost-effective to perform, molecular diagnostic techniques can tailor treatment guidelines to optimize patient's management \[[@B39-antibiotics-09-00388]\].

Our results are in line with an unregistered systematic review and meta-analysis without network comparison but with a precedent search date \[[@B40-antibiotics-09-00388]\].

In conclusion, in this systematic review and NMA CZA monotherapy was as effective as CZA combinations in reducing all-cause mortality in patients with infections by CRE (mostly KPC) but the quality of the available evidence and the overall number of patients from included studies was low.

Further clinical trials should evaluate the effectiveness and safety of different CZA combinations, especially in other infections and clinical settings. Moreover, further evidence is likely to change the outcome estimates.

V.S. was supported by the Programma VALERE, University of Campania "Luigi Vanvitelli". We wish to thank the following authors for they provided additional data and/or full texts upon request: Adrian Sousa, Infectious Diseases Unit-Internal Medicine Department, Hospital Álvaro Cunqueiro, Complejo Hospitalario Universitario de Vigo, Vigo, Spain. Mario Tamburello, Institute of Infectious Diseases, Fondazione Policlinico Universitario A. Gemelli - Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)-Università Cattolica del Sacro Cuore, Rome, Italy

The following are available online at <https://www.mdpi.com/2079-6382/9/7/388/s1>, Table S1: Search strategies for the databases utilized, Table S2: Risk-of-bias assessment in a systematic review of randomized trials, using version 2 of the Cochrane risk-of-bias tool, Table S3: Quality assessment in a systematic review of cohort studies, using the New Castle-Ottawa Scale.

###### 

Click here for additional data file.

Conceptualization, M.F. and A.C.; formal analysis, V.S.; data curation, resources A.A.; data curation, resources S.D.F. and G.I.; writing---original draft preparation, M.F.; writing---review and editing, A.C.; supervision, M.C.P. All authors have read and agreed to the published version of the manuscript.

This research received no external funding.

The authors declare no conflict of interest

![The flow-chart of the study selection.](antibiotics-09-00388-g001){#antibiotics-09-00388-f001}

![This function plots relevant measures quantifying the percentage of direct and indirect evidence proportion, the aggregated minimal parallelism, and a mean path length of a frequentist network meta-analysis model \[[@B30-antibiotics-09-00388]\].](antibiotics-09-00388-g002){#antibiotics-09-00388-f002}

![The graph is a quadratic matrix in which each element in a row is compared to all other elements in the columns. Treatment comparison with only one kind of evidence (i.e., indirect or indirect evidence) are omitted in this plot. The grey boxes for each comparison of designs signify how important a treatment comparison is for the estimation of another treatment comparison. The bigger the box, the more important a comparison is. The colored backgrounds, ranging from blue to red, signify the inconsistency of the comparison in a row attributable to the design in a column. Red is highly inconsistent; blue is a lower value of inconsistency. BAT: Best antibiotic therapy; CZA: Ceftazidime-avibactam monotherapy; comb: Ceftazidime-avibactam combination therapy.](antibiotics-09-00388-g003){#antibiotics-09-00388-f003}

![Number of studies describe how many studies were analyzed for that comparison, with proportion of direct evidence. Direct estimate represents OR and 95%CI directly calculated from real comparison (for example CZA vs. BAT); Indirect estimation is a back-calculation based on other comparison (CZA vs. BAT estimated through CZA vs. comb and BAT vs. comb); Network estimation is a back-calculation based on direct and indirect evidence. BAT: Best antibiotic therapy; CZA: Ceftazidime-avibactam monotherapy; comb: Ceftazidime-avibactam combination therapy.](antibiotics-09-00388-g004){#antibiotics-09-00388-f004}

antibiotics-09-00388-t001_Table 1

###### 

PICOS method for selecting clinical studies in the systematic reviews.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Participants                                                       Intervention                                                     Comparison                    Outcomes                                                                                Study Design
  ------------------------------------------------------------------ ---------------------------------------------------------------- ----------------------------- --------------------------------------------------------------------------------------- -------------------------------------------------------------------
  Adult patients in any setting with confirmed bacterial infection   Ceftazidime-avibactam in association with another antibiotic/s   Ceftazidime-avibactam alone   Primary outcomes: all-cause mortality\                                                  Randomized controlled trials and\
                                                                                                                                                                    Secondary outcomes: (a) not clinical improvement, (b) not microbiological improvement   observational studies (including cohort andcase--control studies)

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

antibiotics-09-00388-t002_Table 2

###### 

Summary of the studies included in the qualitative synthesis.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author (Published Year) \[ref.\]                     Journal                       Study Design   Time Spam      Pathogen         Septic Focus   Evaluation Time Points                    
  ---------------------------------------------------- ----------------------------- -------------- -------------- ---------------- -------------- ------------------------ ---------------- ----------------
  Sousa (2018) \[[@B8-antibiotics-09-00388]\]          J Antimicrob Chemother        RC             04/16--12/17   CRE\             Mix            30-days                  7-days           7-days
                                                                                                                   (KPC: 95%)                                                                

  King (2017) \[[@B26-antibiotics-09-00388]\]          Antimicrob Agents Chemother   RC             03/05--04/16   CRE\             Mix            In Hospital              end of therapy   end of therapy
                                                                                                                   (KPC: 83%)                                                                

  Alraddadi (2019) \[[@B27-antibiotics-09-00388]\]     BMC Infectious Diseases       RC             01/17--08/18   CRE\             Mix            30-days                  30-days          30-days
                                                                                                                   (KPC: 79%)                                                                

  Caston (2017) \[[@B6-antibiotics-09-00388]\]         Int J Infect Dis              RC             06/12--03/16   CRE\             Bacteremia     30-days                  14-days          \-
                                                                                                                   (KPC: 80%)                                                                

  Shields (2017) \[[@B7-antibiotics-09-00388]\]        Antimicrob Agents Chemother   RC             01/09--02/17   CRE\             Bacteremia     30-days                  \-               \-
                                                                                                                   (KPC: 100%)                                                               

  Tumbarello (2019) \[[@B5-antibiotics-09-00388]\]     Clin Infect Dis               RC             04/16--12/17   CRE(KPC: 100%)   Bacteremia     30-days                  \-               In Hospital\*

  Carmeli (2016) \[[@B19-antibiotics-09-00388]\]       Lancet Infect Dis             RCT            01/13--08/14   MIX              cIAI / cUTI    28-days                  7--10 days       21/25-days

  Lucasti (2013) \[[@B21-antibiotics-09-00388]\]       J Antimicrob Chemother        RCT            03/09--12/09   MIX              cIAI           \-                       14-days          14-days

  Qin (2017) \[[@B22-antibiotics-09-00388]\]           Int J Antimicrob Agents       RCT            01/13--03/15   MIX              cIAI           \-                       28--35 days      \-

  Mazuski (2016) \[[@B23-antibiotics-09-00388]\]       Clin Infect Dis               RCT            03/12--04/13   MIX              cIAI           \-                       28--35 days      28--35 days

  Vazquez (2012) \[[@B24-antibiotics-09-00388]\]       Curr Med Res Opin             RCT            11/08--06/10   MIX              cUTI           \-                       5--9 days        5--9 days

  Wagenlehner (2016) \[[@B25-antibiotics-09-00388]\]   Clin Infect Dis               RCT            10/10--08/14   MIX              cUTI           \-                       21--25 days      21--25 days

  Torres (2018) \[[@B20-antibiotics-09-00388]\]        Lancet Infect Dis             RCT            04/13--02/15   MIX              NP             21--25 days              21--25 days      21--25 days
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CRE: carbapenem-resistant Enterobacteriaceae; KPC: Klebsiella pneumoniae carbapenemasi; RC: Retrospective cohort study; RCT: Randomized controlled trial; Mix: Mixed bacterial flora; MIX: Aggregated foci of infection.

antibiotics-09-00388-t003_Table 3

###### 

Summary of the characteristics of enrolled studies in the meta-analysis.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author (Published Year) \[ref.\]                   N° of patients Enrolled   N° of Bacteremia (%)   N° of Patients Treated with CZA Alone   N° of Patients Treated with CZA Association   N° of Patients Treated with BAT   BAT    CZA-Associated Antibiotic   Medical Ward
  -------------------------------------------------- ------------------------- ---------------------- --------------------------------------- --------------------------------------------- --------------------------------- ------ --------------------------- --------------
  Sousa (2018) \[[@B8-antibiotics-09-00388]\]        57                        26 (46)                46                                      11                                            X                                 X      \#                          NS

  King (2017) \[[@B26-antibiotics-09-00388]\]        60                        23 (38)                33                                      27                                            X                                 X      \^                          Mix\
                                                                                                                                                                                                                                                                 ICU (59%)

  Alraddadi (2019) \[[@B27-antibiotics-09-00388]\]   38                        22 (58)                10                                      X                                             28                                §      X                           NS

  Caston (2017) \[[@B6-antibiotics-09-00388]\]       31                        31 (100)               X                                       8                                             23                                \^\^   \^\^                        Mix\
                                                                                                                                                                                                                                                                 ICU (10%)

  Shields (2017) \[[@B7-antibiotics-09-00388]\]      109                       109 (100)              8                                       5                                             96                                ++     \<\>                        Mix\
                                                                                                                                                                                                                                                                 ICU (50%)

  Tumbarello (2019) \[[@B5-antibiotics-09-00388]\]   208                       208 (100)              22                                      82                                            104                               §§     \#\#                        Mix\
                                                                                                                                                                                                                                                                 ICU (33.3%)
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\# colistin iv 5, inhaled colistin 2, tigecycline 2, amikacin 1, imipenem 1. \^ aminoglycosides 40%, polymyxin 26%, tigecycline 22%. § colistin (21, 75%), carbapenem (21, 75%), tigecycline (9, 32.1%), aminoglycoside (8, 28.6%), quinolone (4, 14.3%), trimethoprim/sulfamethoxazole (1, 3.6%) and aztreonam (1, 3.6%). \^\^association of: aminoglycoside (*n* = 7, 87.5%), carbapenems (n = 3, 37.5%), fosfomycin (*n* = 2, 25%), tigecycline (*n* = 2, 25%), colistin (*n* = 2, 25%). ++ carbapenem plus colistin (*n* = 30); carbapenem plus aminoglycoside (*n* = 25); monotherapy consisted of an aminoglycoside (*n* = 11), carbapenem (*n* = 8), colistin (*n* = 4), tigecycline (*n* = 4), ciprofloxacin (*n* = 2); Combination regimens were colistin plus tigecycline (*n* = 3), aminoglycoside plus tigecycline (*n* = 2), and 1 each of aminoglycoside plus cefepime, aminoglycoside plus colistin plus tigecycline, colistin plus aztreonam, colistin plus cefepime, colistin plus ciprofloxacin, carbapenem plus doxycycline, and carbapenem plus tigecycline. \<\> gentamicin. §§ Double carbapenem (*n* = 29, 27.9%); Gentamycin (*n* = 14, 13.5%); Fosfomycin plus amikacin (*n* = 13, 12.5%); Fosfomycin plus gentamycin (*n* = 11, 10.5%); Gentamycin plus meropenem (*n* = 11, 10.5%); Colistin plus fosfomycin (*n* = 10, 9.6%); Colistin (*n* = 9, 8.6%); Others (*n* = 7, 6.7%). \#\# Noncarbapenem drugs (*n* = 63, 76.8%); carbapenem (*n* = 19, 23.17%). Carbapenem-containing regimens included imipenem OR meropenem with or without ertapenem. BAT: Best antibiotic therapy; CZA: Ceftazidime-avibactam; ICU: Intensive care unit; NS: Not specified; Mix: Different type of medical wards.
